NY-ESO-1 Monoclonal Antibody (E978) | Invitrogen 35-6200 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

NY-ESO-1 Monoclonal Antibody (E978)

catalog :

35-6200

quantity :

100 ug

price :

US 451.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

E978

reactivity :

human

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 40

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:200; loading ...; fig s7	Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
flow cytometry; human; fig s1 western blot; human; 1:1000; fig 2b	Klar A, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. PLoS ONE. 2015;10:e0139221 pubmed publisher
immunohistochemistry - paraffin section; human; 1:25	Endo M, de Graaff M, Ingram D, Lim S, Lev D, Briaire de Bruijn I, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015;28:587-95 pubmed publisher
western blot; human; 1:200; fig 1	Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014;38:1332-41 pubmed publisher
immunohistochemistry; human; tbl 1	Dhodapkar M, Sznol M, Zhao B, Wang D, Carvajal R, Keohan M, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6:232ra51 pubmed publisher
western blot; human; fig 2	Krishnadas D, Bao L, Bai F, Chencheri S, Lucas K. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol. 2014;35:5753-62 pubmed publisher
immunocytochemistry; human	Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014;192:523-32 pubmed publisher
immunohistochemistry - paraffin section; human; fig 5	Chen Y, Huang A, Gao M, Yan Y, Zhang W. Potential therapeutic value of dendritic cells loaded with NY?ESO?1 protein for the immunotherapy of advanced hepatocellular carcinoma. Int J Mol Med. 2013;32:1366-72 pubmed publisher
immunohistochemistry; human; fig 1	Beard R, Abate Daga D, Rosati S, Zheng Z, Wunderlich J, Rosenberg S, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res. 2013;19:4941-50 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; fig 2 western blot; human; fig 2	Zimmermann A, Imig J, Klar A, Renner C, Korol D, Fink D, et al. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch. 2013;462:565-74 pubmed publisher
immunohistochemistry - paraffin section; human; fig 1	Xu H, Gu N, Liu Z, Zheng M, Xiong F, Wang S, et al. NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett. 2012;3:39-44 pubmed
immunohistochemistry - paraffin section; human; fig 5	Schuberth P, Jakka G, Jensen S, Wadle A, Gautschi F, Haley D, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013;20:386-95 pubmed publisher
flow cytometry; human; fig 4	Mazzarella T, Cambiaghi V, Rizzo N, Pilla L, Parolini D, Orsenigo E, et al. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Cancer Immunol Immunother. 2012;61:1169-82 pubmed publisher
immunohistochemistry - paraffin section; human; fig 5	Sharma A, Bode B, Wenger R, Lehmann K, Sartori A, Moch H, et al. ?-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE. 2011;6:e28217 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; fig 2	von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE. 2011;6:e21366 pubmed publisher
immunohistochemistry - paraffin section; human; fig 5	Hamai A, Duperrier Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE. 2011;6:e21129 pubmed publisher
western blot; human; fig 1	Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011;60:1299-307 pubmed publisher
flow cytometry; human; fig s7	Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16:800-13 pubmed publisher
flow cytometry; human; fig 4	Hu Y, Cheng S, Chan K, Ke Y, Xue B, Sin F, et al. Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells. Biochem Biophys Res Commun. 2010;392:329-34 pubmed publisher
ELISA; human	Tsai Turton M, Santillan A, Lu D, Bristow R, Chan K, Shih I, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009;114:12-7 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; fig 1	Riener M, Wild P, Soll C, Knuth A, Jin B, Jungbluth A, et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer. 2009;124:352-7 pubmed publisher
immunohistochemistry; human; 1:200; fig 4	Milne K, Barnes R, Girardin A, Mawer M, Nesslinger N, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 2008;3:e3409 pubmed publisher
flow cytometry; human; 1:500; fig 2	Knights A, Nuber N, Thomson C, de la Rosa O, Jager E, Tiercy J, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009;58:325-38 pubmed publisher
immunohistochemistry - paraffin section; human; fig 2a immunocytochemistry; human; fig 2f	Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci. 2008;99:720-5 pubmed publisher
western blot; human	Dubovsky J, Albertini M, McNeel D. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother. 2007;30:675-83 pubmed
immunohistochemistry - paraffin section; human; 1:50; fig 1	Theurillat J, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer. 2007;120:2411-7 pubmed
immunohistochemistry - paraffin section; human; fig 2	Young M, Neville B, Chi A, Lathers D, Boyd Gillespie M, Day T. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2007;56:1077-86 pubmed
immunohistochemistry - paraffin section; human; fig 3	Jacobs J, Brasseur F, Hulsbergen van de Kaa C, van de Rakt M, Figdor C, Adema G, et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer. 2007;120:67-74 pubmed
immunohistochemistry - paraffin section; human; 1:25; fig 2C	Gjerstorff M, Johansen L, Nielsen O, Kock K, Ditzel H. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer. 2006;94:1864-73 pubmed
flow cytometry; human; fig 4	Purbhoo M, Sutton D, Brewer J, Mullings R, Hill M, Mahon T, et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol. 2006;176:7308-16 pubmed
immunohistochemistry - paraffin section; human; 1:100; fig 1	Hadrup S, Braendstrup O, Jacobsen G, Mortensen S, Pedersen L, Seremet T, et al. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer. 2006;119:831-8 pubmed
immunohistochemistry - paraffin section; human; fig 4	Li M, Yuan Y, Han Y, Liu Y, Yan L, Wang Y, et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 2005;11:1809-14 pubmed
	Hou Z, Liang X, Wang X, Zhou Z, Shi G. Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression. Oncol Lett. 2020;19:3982-3992 pubmed publisher
	Punnanitinont A, Kannisto E, Matsuzaki J, Odunsi K, Yendamuri S, Singh A, et al. Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. Int J Mol Sci. 2020;21: pubmed publisher
	Pourmaleki M, Young J, Socci N, Chiang S, Edelweiss M, Li Y, et al. Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. Oncotarget. 2019;10:6152-6167 pubmed publisher
	Camisaschi C, Renne S, Beretta V, Rini F, Spagnuolo R, Tuccitto A, et al. Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients. BMC Cancer. 2018;18:983 pubmed publisher
	Li Y, Song R, Li X, Xu F. Expression and immunogenicity of NY-ESO-1 in colorectal cancer. Exp Ther Med. 2017;13:3581-3585 pubmed publisher
	Singh N, Kulikovskaya I, Barrett D, Binder Scholl G, Jakobsen B, Martinez D, et al. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology. 2016;5:e1040216 pubmed
	Robbins P, Kassim S, Tran T, Crystal J, Morgan R, Feldman S, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019-27 pubmed publisher
	Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer. 2006;118:123-8 pubmed

product information

Product Type :

Antibody

Product Name :

NY-ESO-1 Monoclonal Antibody (E978)

Catalog # :

35-6200

Quantity :

100 ug

Price :

US 451.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Immunohistochemistry (Paraffin): 2.5 ug/mL, Western Blot: 1-3 ug/mL

Species :

Human

Clone :

E978

Isotype :

IgG1

Storage :

Store at 4 C short term. For long term storage, store at -20 C, avoiding freeze/thaw cycles.

Description :

NY-ESO-1, a member of the CT (cancer/testis) family, is a tumor specific shared antigen with distinctive immunogenicity. The molecular basis of T cell-mediated antitumor immunity has been elucidated by the identification of a number of tumor antigens recognized by CD8+ T cells. Among these antigens, NY-ESO-1 is of particular interest because both the cytotoxic T lymphocyte and antibody have been shown to react with this antigen. The NY-ESO-1 has been detected in normal testis and in a range of human tumor types. NY-ESO-1 reactivity in testis is restricted germ cells, particularly in the spermatogonia.

Immunogen :

Human NY-ESO-1 recombinant protein

Format :

Liquid

Applications w/Dilutions :

Immunohistochemistry (Paraffin): 2.5 ug/mL, Western Blot: 1-3 ug/mL

Aliases :

Autoimmunogenic cancer/testis antigen NY-ESO-1; cancer/testis antigen 1; cancer/testis antigen 1A; cancer/testis antigen 1-A; cancer/testis antigen 6.1; CT6.1; CTAG; CTAG1; CTAG1A; CTAG1B; ESO1; l antigen family member 2; LAGE2; LAGE-2; LAGE2A; LAGE2B; New York Esophageal Squamous Cell Carcinoma 1; NY-ESO-1

more info or order :

Invitrogen product webpage